Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05286619

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) (PIPER)

Sponsor: Cancer Research Malaysia

Conditions Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions Carboplatin Cisplatin Gemcitabine Pembrolizumab

Updated 8 times since 2022 Last updated: Oct 9, 2024 Started: Sep 22, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by Cancer Research Malaysia and has accumulated 8 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Nov 2024 — Present [monthly]

Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Dec 2022 — Jun 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE2
Apr 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Research Malaysia
Kuala Lumpur General Hospital
Merck Sharp & Dohme LLC
My Starfish Foundation
National Cancer Institute, Malaysia
University of Malaya
Yayasan PETRONAS
Yayasan Sime Darby

Data source: University of Malaya

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kuala Lumpur, Malaysia